With the United States Environmental Protection Agency (EPA) Evotec entered into a multi-year compound management agreement. The contract covers a period of five years and has a total value of up to € 7.7 m (approximately $ 10 m).
With the National Institutes of Health (NIH) Evotec signed a multi-year agreement for the operation of a small molecule repository (SMR). The contract is funded in its entirety by NIH, covers a period of up to 10 years and has a total estimated value of up to € 60 m (approximately $ 75 m).
With 4-Antibody Evotec acquired access to a fully integrated antibody discovery and development service. Evotec's novel and unique high throughput and high content screening approach coupled with 4-Antibody's high throughput antibody selection approach will allow screening of large and diverse antibody populations for desired functionality and activity at a much earlier stage of selection. This unique combined approach is expected to substantially reduce attrition rates at later development stages.
Signed in December 2012 and effective 01 January 2013, Evotec acquired Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and pharmaceutical companies. CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes and proteins for high throughput screening with more than 10 years experience in bulk cell production.EVT Integrate – New strategic multi-target alliance with Bayer and several key milestone achievements With Bayer Evotec entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Evotec received € 12 m as an upfront payment. In total, Evotec could receive pre-clinical, clinical and sales milestones of up to € 580 m plus royalties. Under the terms of the deal both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of candidates in endometriosis.